Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study

[1] Rawshani A(2018)Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med 379 633-44

[2] Rawshani A(2015)The remnants of residual risk J Am Coll Cardiol 65 2276-8

[3] Franzen S(2019)The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk Endocr Rev 40 537-57

[4] Sattar N(2016)Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol Diabetes 65 1767-78

[5] Eliasson B(2014)Triglycerides and cardiovascular disease Lancet (London England) 384 626-35

[6] Svensson AM(2014)Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 203-12

[7] Zethelius B(2017)Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease N Engl J Med 376 1933-42

[8] Miftaraj M(2007)Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 299-308

[9] McGuire DK(2020)Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease J Am Coll Cardiol 76 2712-24

[10] Rosengren A(2013)Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation Circulation 128 1298-309

[1] Rawshani A(2018)Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med 379 633-44

[2] Rawshani A(2015)The remnants of residual risk J Am Coll Cardiol 65 2276-8

[3] Franzen S(2019)The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk Endocr Rev 40 537-57

[4] Sattar N(2016)Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol Diabetes 65 1767-78

[5] Eliasson B(2014)Triglycerides and cardiovascular disease Lancet (London England) 384 626-35

[6] Svensson AM(2014)Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 203-12

[7] Zethelius B(2017)Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease N Engl J Med 376 1933-42

[8] Miftaraj M(2007)Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 299-308

[9] McGuire DK(2020)Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease J Am Coll Cardiol 76 2712-24

[10] Rosengren A(2013)Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation Circulation 128 1298-309